SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Rights Issue
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
4/18/2024
Diamyd Medical announces final outcome in the company’s rights issue
4/16/2024
Diamyd Medical announces preliminary outcome in the company’s rights issue
4/12/2024
Recruitment milestone reached in Diamyd
®
Phase 3 trial
4/11/2024
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes
4/5/2024
Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue
3/28/2024
Diamyd Medical publishes prospectus with regards to the rights issue
3/27/2024
Quarterly Report II 23/24
3/18/2024
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million
2/29/2024
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA
2/15/2024
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd
®
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research